Key result
High baseline hemoglobin glycation index (HGI) in the ACCORD trial was analyzed using baseline HbA1c and fasting plasma glucose to address comments on its validity.
Answers are grounded in this paper and cite their sources.
This is a response to a comment regarding the use of the Hemoglobin Glycation Index to identify subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
Drs. Riddle and Gerstein (1) suggest renaming the hemoglobin glycation index (HGI) to reflect the possibility that interindividual variation in HGI in the ACCORD trial could be an artifact of how blood glucose was measured. HGI is the difference between an individual’s observed HbA1c and a predicted HbA1c derived by inserting a time-matched blood glucose measurement into a regression equation describing the linear population relationship between blood glucose and HbA1c. In our analysis of ACCORD (2), we used baseline HbA1c and fasting plasma glucose (FPG) to show that high HGI at baseline (i.e., HbA1c higher than predicted by FPG) was …
No takes yet. Share an insight, caveat, or question.
Hempe et al. (2015) conducted a letter in Diabetes. Hemoglobin glycation index (HGI) was evaluated. High baseline hemoglobin glycation index (HGI) in the ACCORD trial was analyzed using baseline HbA1c and fasting plasma glucose to address comments on its validity.
Synapse has enriched 10 related papers. Consider them for comparative context: